Endothelial Barrier Disruption by VEGF-mediated Src Activity Potentiates Tumor Cell Extravasation and Metastasis

Overview

Journal J Cell Biol

Specialty Cell Biology

Date 2004 Oct 27

PMID 15504909

Citations 208

Authors

Sara Weis

Jianhua Cui

Leo Barnes

David Cheresh

Affiliations

Soon will be listed here.

Abstract

VEGF is unique among angiogenic growth factors because it disrupts endothelial barrier function. Therefore, we considered whether this property of VEGF might contribute to tumor cell extravasation and metastasis. To test this, mice lacking the Src family kinases Src or Yes, which maintain endothelial barrier function in the presence of VEGF, were injected intravenously with VEGF-expressing tumor cells. We found a dramatic reduction in tumor cell extravasation in lungs or livers of mice lacking Src or Yes. At the molecular level, VEGF compromises the endothelial barrier by disrupting a VE-cadherin-beta-catenin complex in lung endothelium from wild-type, but not Yes-deficient, mice. Disrupting the endothelial barrier directly with anti-VE-cadherin both amplifies metastasis in normal mice and overcomes the genetic resistance in Yes-deficient mice. Pharmacological blockade of VEGF, VEGFR-2, or Src stabilizes endothelial barrier function and suppresses tumor cell extravasation in vivo. Therefore, disrupting Src signaling preserves host endothelial barrier function providing a novel host-targeted approach to control metastatic disease.

Citing Articles

Small Fish, Big Answers: Zebrafish and the Molecular Drivers of Metastasis.

Martinez-Lopez M, Lopez-Gil J Int J Mol Sci. 2025; 26(3).

PMID: 39940643 PMC: 11817282. DOI: 10.3390/ijms26030871.

Tumor microbiome: roles in tumor initiation, progression, and therapy.

Zhang S, Huang J, Jiang Z, Tong H, Ma X, Liu Y Mol Biomed. 2025; 6(1):9.

PMID: 39921821 PMC: 11807048. DOI: 10.1186/s43556-025-00248-9.

PCDH17 induces colorectal cancer metastasis by destroying the vascular endothelial barrier.

Dong F, Zhou P, Kong F, Cao S, Pan X, Cai S Cell Death Dis. 2025; 16(1):36.

PMID: 39837826 PMC: 11750977. DOI: 10.1038/s41419-025-07355-z.

Serum from Hypertensive Patients Induces Cancer-Supporting Phenotype of Vascular Endothelium In Vitro.

Uruski P, Mikula-Pietrasik J, Tykarski A, Ksiazek K Biomolecules. 2024; 14(11).

PMID: 39595551 PMC: 11592052. DOI: 10.3390/biom14111374.

Biological Roles and Clinical Therapeutic Applications of Tumor-Associated Macrophages in Colorectal Liver Metastasis.

Li S, Hao L, Hu X J Inflamm Res. 2024; 17:8429-8443.

PMID: 39529996 PMC: 11552512. DOI: 10.2147/JIR.S493656.

References

Esser S, Lampugnani M, Corada M, Dejana E, Risau W . Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci. 1998; 111 ( Pt 13):1853-65. DOI: 10.1242/jcs.111.13.1853. View

Xiang R, Lode H, Dolman C, Dreier T, Varki N, Qian X . Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res. 1997; 57(21):4948-55. View

ROWE D, Huang J, Kayton M, Thompson R, Troxel A, OToole K . Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg. 2000; 35(1):30-2; discussion 32-3. DOI: 10.1016/s0022-3468(00)80008-1. View

Liao F, Li Y, OConnor W, Zanetta L, Bassi R, Santiago A . Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. Cancer Res. 2001; 60(24):6805-10. View

Paul R, Zhang Z, Eliceiri B, Jiang Q, Boccia A, Zhang R . Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat Med. 2001; 7(2):222-7. DOI: 10.1038/84675. View

Boschelli D, Ye F, Wang Y, Dutia M, Johnson S, Wu B . Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem. 2001; 44(23):3965-77. DOI: 10.1021/jm0102250. View

Liao F, Doody J, Overholser J, Finnerty B, Bassi R, Wu Y . Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability. Cancer Res. 2002; 62(9):2567-75. View

Hood J, Bednarski M, Frausto R, Guccione S, Reisfeld R, Xiang R . Tumor regression by targeted gene delivery to the neovasculature. Science. 2002; 296(5577):2404-7. DOI: 10.1126/science.1070200. View

Nam J, Ino Y, Sakamoto M, Hirohashi S . Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res. 2002; 8(7):2430-6. View

10.

Bruns C, Shrader M, Harbison M, Portera C, Solorzano C, Jauch K . Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer. 2002; 102(2):101-8. DOI: 10.1002/ijc.10681. View

11.

Zhang L, Yang N, Mohamed A, Benencia F, Rubin S, Allman D . Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol. 2002; 161(6):2295-309. PMC: 1850900. DOI: 10.1016/s0002-9440(10)64505-1. View

12.

Golas J, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J . SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 2003; 63(2):375-81. View

13.

Ferrara N, Gerber H, LeCouter J . The biology of VEGF and its receptors. Nat Med. 2003; 9(6):669-76. DOI: 10.1038/nm0603-669. View

14.

Recchia I, Rucci N, Festuccia C, Bologna M, Mackay A, Migliaccio S . Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur J Cancer. 2003; 39(13):1927-35. DOI: 10.1016/s0959-8049(03)00394-0. View

15.

Boguslawski G, McGlynn P, Harvey K, Kovala A . SU1498, an inhibitor of vascular endothelial growth factor receptor 2, causes accumulation of phosphorylated ERK kinases and inhibits their activity in vivo and in vitro. J Biol Chem. 2003; 279(7):5716-24. DOI: 10.1074/jbc.M308625200. View

16.

Weis S, Shintani S, Weber A, Kirchmair R, Wood M, Cravens A . Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest. 2004; 113(6):885-94. PMC: 362122. DOI: 10.1172/JCI20702. View

17.

Senger D, Van de Water L, Brown L, Nagy J, Yeo K, Yeo T . Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993; 12(3-4):303-24. DOI: 10.1007/BF00665960. View

18.

Eliceiri B, Paul R, Schwartzberg P, Hood J, Leng J, Cheresh D . Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell. 2000; 4(6):915-24. DOI: 10.1016/s1097-2765(00)80221-x. View